Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 455

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Open access
Westin, Jason R., Oluwole, Olalekan O., Kersten, Marie José, Miklos, David B., Perales, Miguel-Angel, Ghobadi, Armin, Rapoport, Aaron P., Sureda, Anna, Jacobson, Caron A., Farooq, Umar, van Meerten, Tom, Ulrickson, Matthew, Elsawy, Mahmoud, Leslie, Lori A., Chaganti, Sridhar, Dickinson, Michael, Dorritie, Kathleen, Reagan, Patrick M., McGuirk, Joseph, Song, Kevin W., Riedell, Peter A., Minnema, Monique C., Yang, Yin, Vardhanabhuti, Saran, Filosto, Simone, Cheng, Paul, Shahani, Shilpa A., Schupp, Marco, To, Christina, Locke, Frederick L.·2023·New England Journal of Medicine

Abstract

BACKGROUND: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-free survival than those who received standard care. Data were needed on longer-term outcomes. METHODS: In this trial, we randomly assigned patients with early relapsed or refractory large B-cell lymphoma in a 1:1 ratio to receive either axi-cel or standard care (two to three cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem-cell transplantation in patients who had a response). The primary outcome was event-free survival, and key secondary outcomes were response and overall survival. Here, we report the results of the prespecified overall survival analysis at 5 years after the first patient underwent randomization. RESULTS: A total of 359 patients underwent randomization to receive axi-cel (180 patients) or standard care (179 patients). At a median follow-up of 47.2 months, death had been reported in 82 patients in the axi-cel group and in 95 patients in the standard-care group. The median overall survival was not reached in the axi-cel group and was 31.1 months in the standard-care group; the estimated 4-year overall survival was 54.6% and 46.0%, respectively (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.54 to 0.98; P = 0.03 by stratified two-sided log-rank test). This increased survival with axi-cel was observed in the intention-to-treat population, which included 74% of patients with primary refractory disease and other high-risk features. The median investigator-assessed progression-free survival was 14.7 months in the axi-cel group and 3.7 months in the standard-care group, with estimated 4-year percentages of 41.8% and 24.4%, respectively (hazard ratio, 0.51; 95% CI, 0.38 to 0.67). No new treatment-related deaths had occurred since the primary analysis of event-free survival. CONCLUSIONS: At a median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed or refractory large B-cell lymphoma resulted in significantly longer overall survival than standard care. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2301665

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 455

Metadata

Authors
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., van Meerten, T., Ulrickson, M., Elsawy, M., Leslie, L. A., Chaganti, S., Dickinson, M., Dorritie, K., Reagan, P. M., McGuirk, J., Song, K. W., Riedell, P. A., Minnema, M. C., Yang, Y., Vardhanabhuti, S., Filosto, S., Cheng, P., Shahani, S. A., Schupp, M., To, C., & Locke, F. L.
Venue
New England Journal of Medicine
Published
2023-07-13
Volume
389
Issue
2
Pages
148-157
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4379375856
Cited by
455
References
29
FWCI
47.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1056/nejmoa2301665
The paper
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., van Meerten, T., Ulrickson, M., Elsawy, M., Leslie, L. A., Chaganti, S., Dickinson, M., Dorritie, K., Reagan, P. M., McGuirk, J., . . . Locke, F. L. (2023). Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2301665

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.